Special Issue

Peptide-Drug Conjugates for Targeted Delivery

Message from the Guest Editors

Tumor targeting is an appealing approach that is often invoked to selectively eliminate malignant tumor cells and spare the surrounding healthy tissues. Peptides represent a dominant aspect of this approach due to their biocompatibility, substantial tumor specificity, impressive ability to penetrate tissue, cell internalization, and relatively low production cost. In addition, peptides can specifically attach to cell surface receptors and proteins. The peptides that enter cells can bind to intracellular proteins and disrupt their interactions. Tethering such tumor-homing peptides with toxic warheads (anticancer drugs) via various linkers results in the formulation of tumor-targeting Peptide–Drug Conjugates (PDCs).

This Special Issue will focus on the extensive application of PDCs, with a scope including, but not limited to, the following topics: 1) The design, synthesis, and evaluation of novel peptide–drug conjugates that may exert therapeutic, diagnostic, or theragnostic effects; 2) Synthetic methodologies that facilitate the construction of PDCs; and 3) The implementation of nanoformulations that ameliorate the therapeutic efficacy of PDCs.

Guest Editors

Dr. Eirinaios I. Vrettos

St. Jude Children's Research Hospital, Department of Chemical Biology & Therapeutics, 262 Danny Thomas Place, Memphis, TN, USA

Dr. Sankarprasad Bhuniya

Centre for Interdisciplinary Sciences, JIS Institute of Advanced Studies and Research, JIS University, West Bengal 700091, India

Deadline for manuscript submissions

31 May 2026



Pharmaceutics

an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



mdpi.com/si/205226

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

mdpi.com/journal/pharmaceutics





an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ 08854, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).

